This essay has been submitted by a student. This is not an example of the work written by our professional essay writers.
Following the identification of a Non-A, non-B viral hepatitis (NANBH) in 1975 that had been found to be associated with blood transfusion in majority, efforts were concentrated to identify the distinct virus. Finally, in 1989 Choo and coworkers of Chiron Co-operation group were able to discover a single-stranded RNA virus of 9.5kb and 40-50 nm diameter that belongs to Flaviviridae and recognized as Hepatitis C virus (HCV) (1-4). Even though humans are the only known host for HCV, experimental transmission of HCV has been established in to the chimpanzees (5).
Scope of hepatitis C
Hepatitis C could manifests as acute or chronic infection. In general acute hepatitis C presents as milder disease and only up to 20-30% individuals develop symptoms (5). However, up to 80% cases are predisposed to develop chronic infection and subsequently up to 20% individuals develop cirrhosis within 20-30 years in up to 20% cases. Following the development of cirrhosis there is a significant risk to develop hepatocellular carcinoma (HCC) (5-7). Globally up to 27% cases of cirrhosis and 25% HCC have been estimated to due to HCV (12).Nonetheless, 7,96000 and 6,16000 deaths were attributed to cirrhosis and primary hepatocellular carcinoma in 2002(8) and perhaps up to 20% of these deaths were attributable to HCV infection(9). 20%, 70%, 40%, 60% and 30% cases of acute hepatitis, chronic hepatitis, cirrhosis, HCC and liver transplants respectively is of alarming for industrialized countries where the access to health care facilities are relatively easy(10). On the other hand inadequate detection, non-availability of treatment due to high cost in developing countries are the main factors leading to increase number of untreated patients as well as increase mortality due to HCV related liver (8). Hence, the chronicity of HCV infection leading to major complications has made HCV a major health care burden globally.
Economic burden of hepatitis C
The tendency to develop chronic disease and subsequent complications including HCC justifies early detection and treatment of HCV infection. The improvement in sustained viral response with currently available pegylated interferon and ribavirin therapy favors treatment of eligible patients. Similarly, liver transplantation improves the survival for patients with decompensated cirrhosis and HCC. However, the cost of antiviral therapy and liver transplantation is very high and is huge socioeconomic and health burden especially for developing countries(11). Moreover, unavailability of liver transplantation and referrals to centers other than native country adds further cost.
Global burden of hepatitis C
HCV is the most common cause of transfusion related hepatitis that affects in general 3% or 170 million individuals throughout the world. However, the prevalence of hepatitis C varies widely with the geographical locations as well as within the populations(12). The prevalence of chronic hepatitis C ranges from 0.1 to 5% in different countries (3, 10)
The WHO prevalence was higher in some countries in Africa (5.3% or 31.9 million), the eastern Mediterranean (4.6% or 21.3 million), South-East Asia (2.15% or 32.3 million) and the Western Pacific (3.9% or 62.2 million), as compared with some countries in the Americas (1.7% or 13.1 million) and Europe (1.03% or 8.9 million)(9).
In 2004, the Global Burden of Hepatitis C Working Group, serving as a consultant to the WHO, estimated the global prevalence to be slightly lower at 2.2% or 130 million individuals. The lowest HCV prevalence of 0.01% to 0.1% is from countries in the United Kingdom and Scandinavia, while the highest prevalence of 15% to 20% is from Egypt (3). North America 2%(13)
The incidence of new symptomatic infection has been estimated to be 1-3 cases/ 1 000 000 persons annually. The actual incidence of new infections is obviously much higher (the majority of cases being asymptomatic). The incidence is declining for two reasons: (a) transmission by blood products has been reduced to near zero and (b) universal precautions have markedly reduced transmission in medical settings. Intravenous drug use remains the main mode of transmission, but, even here, the rate of transmission is diminishing due to a heightened awareness of the risk of needle sharing and, in some countries, the availability of needle-exchange programmes(10).
In France, the prevalence of anti-HCV-positive adults is estimated to be between 1.1 and 1.2%, out of whom 80% are viraemic. Therefore, it is estimated that 400 000-500 000 subjects have chronic HCV infection. The prevalence varies widely in different populations: 60% in intravenous drug users, 25% in incarcerated subjects and 25% among HIV-positive patients (25 000-30 000 subjects have HCV/HIV co-infection)( Consensus Conference. Treatment of hepatitis C. Guidelines.GastroentÂ´erol Clin Biol 2002; 26: B312-20).
In United States of America (USA)CHC is the leading cause of liver transplantation (14) and between 1990-2000 five-fold increase in annual number of liver transplantations for patients with HCV has been reported (15). Centers for Disease Control (CDC) conduct National Health and Nutrition Examination Survey (NHANES) periodically in USA. According to a recent NHANES (1999-2002) 1.6% 4.1 million people found seropositive for HCV(16). However, further evaluation by testing HCV RNA reveled 1.3% or 3.2 million individuals affected by chronic hepatitis C infection(17). Furthermore, the HCV prevalence was higher among men (2.1% vs. 1.1%), non-Hispanic blacks than whites (91.5% vs. 3%) and Mexican Americans (1.3%). Although the overall HCV prevalence was nearer to 1.8% (18) that was found in NHANES III (1988-1994) an upward shift of peak age group infected was reported from 45 to 49 years (NHANES IV) to 35 to 39 years (NHANES III). This was probably due to involvement of most individuals belonging to birth cohort between 1945- 1964(16). Earlier than the implementation of universal screening of blood donors in 1992, transfusion of contaminated blood and blood products was the principal mode of responsible for HCV transmission. Whereas currently IVDU and percutaneous exposure due to high-risk sexual behaviors are the major factors responsible for HCV spread(3). However, one should keep this in mind that underrepresentation of incarcerated and homeless individuals in NHANES data might have lead to underestimation of overall HCV prevalence (22).
In a study conducted in 2002 all new entrants into the Maryland Division of Correction and the Baltimore City Detention Center were evaluated between 28 January and 28 March 2002. 29.7% Out of 3914 inmates and detainee, 29.7% were found to be affected by HCV(19). Moreover, 44% of 418 homeless veterans were found affected by HCV in another study that was significantly associated with history of substance abuse (odds ratio 6.86, P < 0.001] and service during the Vietnam era (OR 4.66, P 0.01)(20).
Although the overall estimated numbers of incident HCV cases have been declined to 30,000/year (21, 22), HCV-associated morbidity and mortality have been predicted to increase significantly in next 20-30 years due to the chronicity related to HCV (3, 15, 22-24). Currently the estimated HCC development rate among patients with cirrhosis in USA is 3%-4% /year (25) that has been equivalent to three folds increase than 1993(26). Moreover, HCV is estimated to cause 8000 to 10,000 deaths per year related to liver complications and HCC(3).
In Canada, the estimated prevalence of HCV infection is 0.8% and majority of the cases lies between 15 to 39 years of age. According to the national "Enhanced Hepatitis Strain Surveillance System", the incidence of HCV per 100,000 individuals has been declined from 3.3 to 2.1 cases from 1998 to 2004. (Public Health Agency of Canada. Evaluation of the hepatitis C prevention, support and research program 1999/2000-2005/2006. Available at: http://www.phac-aspc.gc.ca/publicat/2008/er-re-hepc/er-re-hepc1-eng.php#ref. Accessed March 9, 2009). This decline is attributed to the safe blood transfusion practices. Currently IDU is the major factor associated with HCV spread, however the sexual transmission found uncommon(27).
In Latin America, in general HCV seroprevalence is 1.23% with some variability from region to region that ranged 0.2-3.4%. Blood transfusion and high risk sexual behaviors were found to be the main risk factors associated with HCV (28, 29).
In England 0.6% of adult population aged 15-59 have been found to be affected by HCV. However, this proportion represents a decline from 1.07% HCV prevalence that has been documented in 1986. According to the estimations of UK Health Protection Agency, among people affected by HCV approximately 6000 and 1500 individuals will develop cirrhosis and end-stage liver disease or HCC respectively by 2010 and further increase in these rates are expected in next decades (30-32). Furthermore, in a cross sectional study by Balogun and colleague(33) changes in HCV sero-prevalence was studied in general population of England. Sera of adult patients submitted to 19 laboratories of England were tested to determine average HCV prevalence between 1986 and 2000. The results showed HCV seroprevalence 1.07(39/3647), 0.55(31/5634), 0.73(43/5924) and 1.20(61/5068) for the year 1986, 1991, 1996 and 2000 respectively. Higher HCV prevalence was found among males and birth cohort of 1950-1970. Moreover, higher HCV prevalence was found in London (1.27), Eastern (1.41) and South West (1.25) regions of UK.
IDUs have been found to be at the highest risk to acquire HCV in UK (34). IDUS usually begins in late adolescence and early adulthood. Considering lower HCV prevalence in general population and greater HCV acquisition risk with IDU focused and targeted strategies are required to identify high risk populations and to implement preventive strategies to avoid HCV transmission via IDU in (33, 35, 36).
According to the WHO estimates 5.3% or 31.9 million individuals are affected by hepatitis C in Africa(6). However, variability in different regions of Africa have been found like 6%, 2.4% and 1.6% HCV prevalence have been found in Central Africa, west Africa and east Africa respectively. Furthermore, clusters of higher prevalent areas have been notified like Burundi with 11.3% and Cameroon with 13.8% HCV prevalence(37). The individuals > 40 years of age are affected mostly. Like other developing countries unsafe therapeutic injections and blood transfusions are the most common attributable factor responsible for HCV spread. Whereas, beside the cases with HCV and HIV co-infection vertical transmission is uncommon and so is correct for IDU (38-41).
The WHO estimated prevalence of HCV in the Eastern Mediterranean region is 4.6% or 21.3 million(6). This region includes Egypt, the largest reservoir of HCV in the world with its prevalence rate of 11% to 14% or 8 to 10 million inhabitants, of whom 5 to 7 million have active viremia(42, 43). The major source of infection is exposure to intravenous tartar emetic that was used to control schistosomiasis 20 to 50 years ago(44). The rate of infection is lowest in Cairo and Alexandria at 8%, intermediate in rural areas along the Nile south of Cairo (Middle and Upper Egypt) at 8% to 16%, and highest in rural areas of Nile Delta or Lower Egypt, at 15%(43).The infection is more common in males and in older individuals.103
The large reservoir of HCV among the older Egyptians allowed for efficient transmission via infected blood products and medical equipment(43).Hepatitis C is the cause of most cases of HCC (60% to 78.5%) in this country(45). Of note, more than 90% of HCV infections are due to genotype 4(46).Another country with high endemicity for HCV is Pakistan. The Pakistan Medical Research Council estimate the prevalence of HCV at 4.9% or 8.8 million people.49
The prevalence of the disease has increased since 2005, when the Prime Minister Program for Prevention and Control of Hepatitis started to provide free treatment to poor patients on a limited scale, and more people underwent testing and sought treatment. The pattern of transmission in Pakistan is not well documented, but parenteral exposure to infected needles and blood are believed to be important risk factors. Inaddition, community barber shops where infected razors can transmit the infection are another route. IVDU and sexual transmission are minor contributors in HCV transmission in this country(47).
The WHO South-East Asia region has an estimated HCV prevalence of 2.15% or 32.3 million individuals(9). Availability of data on member states is limited, but a summary of published reports as well as on WHO estimates was presented in 1999 (Table 1), with the exception of Timor-Leste, which had not yet gained its independence from Indonesia at that time. India is the most populated country in this region, but data on the prevalence of HCV in the general population is scant. Whereas HCV prevalence is estimated at 1.5% to 4.3% in voluntary blood donors,(48) a few population-based studies reported a prevalence of 0.71% to 2.02%(48). On the other hand, HCV prevalence is even more significantly higher in commercial blood donors at 55.3% to 87.3%(49). In the most systematic population-based study performed in West Bengal involving 10,737 inhabitants from 9 villages, the HCV infection was directly proportional to the
age, with the highest prevalence in the age group older than 60 years and the lowest in the age group younger than 10 years. No gender difference was observed(50). Hepatitis C is incriminated as the cause of liver cirrhosis in 3.3% to 31.5% of cases and of HCC in 15.1% to 42% of cases(17). The major source of transmission is transfusion of blood and blood products, although the rate has been decreasing since the mandatory screening for HCV in blood donors has been introduced as late as 2002 in some areas.113 IVDU is a significant problem in north-east India and the rest of the
country, and in the only study that addressed the prevalence of HCV in this population,
an alarming 92% was reported in 77 intravenous drug users from Manipur Saha.
Hemodialysis is another risk factor, with prevalence rates of 4.3% to 28% being
observed in dialyzed patients. Health care workers, particularly dentists, are also at
In Thailand, the prevalence of HCV antibody is 1.37% to 2.9% in voluntary blood
Donors (51, 52), with a 2:1 ratio amongst males to females(52). Intravenous drug use is
the most common route of transmission, followed by previous blood or blood product
transfusion, sharing of razors, and unsafe injection practices(53). The prevalence is as
high as 86% to 92.5% in the IVDU populations(53, 54), while commercial sex workers
also have a prevalence rate of 9.5%(55).
In Indonesia, the prevalence of HCV is 2.1% in blood donors, in whom prior blood
transfusion, IVDU, surgery, and acupuncture were identified as risk factors(56). In
Myanmar, 2.5% of the 363 healthy subjects were found to be positive for HCV in
2002(Kyi KP, Aye M, Oo KM, et al. Population and patients with liver ailments in Myanmar. Reg Health Forum 2002;6(1):1-6. Available at: http://www.searo.who.int/EN/Section1243/Section1310/Section1343/Section1344/Section1355_
5302.htm. Accessed March 11, 2009)
The WHO Western Pacific region has an estimated HCV prevalence of 3.9% or 62.2
million people(9). Due to the high endemicity of HBV in this region, fewer data are available
on HCV. About 3.2% of China's population, or 38 million individuals, were found
to have HCV in a national epidemiologic survey done in 1992 to 1995. The most important
means of transmission is IVDU, and the HCV incidence in the intravenous drug
user cohort is as high as 3.6 cases per 100 person-years(57). The pooled HCV infection
rate among the IVDU population throughout the country was 61.4%, with the risk
increasing with duration of IVDU as well as with HIV coinfection(58). In Japan, the estimated HCV prevalence is 2% or 2 million people(59). The prevalence is directly proportional to age, with the highest rate of 7% seen in individuals older than 70 years(60). The modes of transmission include blood transfusions, IVDU, and unsafe needle use in medical practice before 1980. Hepatitis C is the major etiological factor for HCC in Japan, where HBV is not endemic(61).
In Australia, the estimated HCV prevalence was 210,000 at the end of 2001, and the
estimated incidence of new HCV infection was higher at 16,000 in 2001 compared with
11,000 in 1997(62). About 80% to 90% of HCV infections are attributed to IVDU, and
the increasing prevalence is attributed to the increasing prevalence of this practice
despite the introduction of needle and syringe programs in the late 1980s(63). In
contrast, Samoa and American Samoa have a low HCV prevalence, estimated at
0.2% to 0.6% of the population, which is reflective of the low rate of IVDU as well
as unsafe medical practices in these countries(64).
Over the period 1990-2000 approximately 160 000 notifications of HCV infection were received by State and Territory health jurisdictions making it the most commonly notified communicable disease in Australia. Approximately 210 000 people are estimated to be living with HCV infection in Australia, with an estimated 80% having acquired their infection through injecting drug use. Less than 500 cases of newly acquired HCV infection are notified each year, however, an estimated 16 000 new infections occur annually. Despite the widespread introduction of needle and syringe programmes in the late 1980s, HCV transmission continues at high levels among current injecting drug users (IDUs) with incidence and prevalence estimates of 10-20/
100 person years and 50-55%, respectively. Levels of HCV transmission are particularly high in both younger and incarcerated IDUs. In contrast to HCV infection, prevalence of HIV among current IDUs has remained below 2% since 1995. Although a small minority of people with chronic HCV infection will develop liver failure or hepatocellular carcinoma, the incidence of these advanced disease complications is estimated to double over the next decade.
5 million HCV carriers in western Europe(10)
France 1.1-1.2%, 400 000-500 000 subjects have chronic HCV infection (Consensus Conference. Treatment of hepatitis C. Guidelines. GastroentÂ´erol Clin Biol 2002; 26: B312-20)
scarcity of HCV incidence data that are comparable across countries of the WHO European region. Pan-European HCV incidence data available from the WHO Health for All Database
[World Health Organization: WHO Health for all database. 2006 [http://data.euro.who.int/hfadb], which presents annual case numbers of acute hepatitis C (ICD-10 Code B17.1) submitted by countries of the WHO European region, proved to be the most comparable due to the use of a standardised case-definition. Data were available for the period 1997 to 2004. All countries except Monaco and Turkey provided at least one estimate, and only a few countries reported data on an annual basis.
To cope with temporal variation, we averaged annual incidence figures reported during the observed time period.
Averaged annual incidence rates for acute hepatitis C vary across countries from 0.00 to 39.21 cases per 100000 residents. However, the geographic distribution of incidence rates in the WHO European region shows no clear pattern. Applying a population size weight yielded an average annual incidence rate of 6.19 per 100000 (95% CI 4.90-7.48) for the
WHO European region (excluding Monaco and Turkey)(65).
According to the WHO prevalence estimates for 32 countries of the European region HCv prevalence rage 0.003% to 4.5% with the higher rates of >1.25 in Southern and Eastern European countries and lower i.e â‰¤ 0.1% rates in Northern Europe.
According to WHO prevalence data, approximately 7.3 million (1.1%) people in our 22 focus countries are estimated to be infected with HCV. Based on the higher national estimates, 8.8 million (1.3%) people are estimated to be infected. HCV caused more than 86000 deaths in the WHO European region in 2002, accounting for 35% of cirrhosis and 32% of liver cancer deaths in that year. Country-specific HCV-related mortality ranges from 0.1 to 31.5 deaths(65)
per 100000 residents. High death rates (> 12 deaths per 100000) are predominantly found in the centre of the region. HCV-related liver cancer mortality (Figure 4) displays a notable East-West
gradient, with high death rates (> 3 per 100000) in Western Europe and low death rates (<= 1 per 100000) in Eastern Europe. The death rates for HCV-related cirrhosis (Figure 5) provide a complementary picture(65).
Mediterranean and some Asians countries 3-4%(13)
Central Africa and Egypt 10%(13)
There are 11 HCV genotypes (genotypes 1 to 11), many subtypes (a, b, c, and so forth), and about 100 different strains (1, 2, 3, and so forth) based on the sequence heterogeneity of the HCV genome. Genotypes 1 to 3 are widely distributed globally, with genotypes 1a and 1b accounting for 60% of infections worldwide. Genotype 1a is predominantly located in Northern Europe and North America, while genotype 1b is predominantly found in Southern and Eastern Europe and Japan. Genotype 2 is less common than genotype 1, and is found more in Europe than in North America. Genotype 3 is endemic in South-East Asia, and genotype 4 is characteristic for the
Middle East, Egypt, and central Africa. Genotype 5 is almost exclusively found in South Africa, and genotypes 6 to 11 are mostly distributed in Asia The impact of viral genotype in the pathogenesis of liver disease remains a subject of controversy, but the influence of the genotype in the response to interferon-based therapy is established. Genotype 1 is generally associated with a poorer response to therapy while genotypes 2 and 3 have a more favorable response. Genotype 4 seems to have an intermediate response (16, 66). A larger survey, of 6807 U.S. patients with CHC, found that 73% of patients were infected with HCV genotype 1, 14% with genotype 2, 8% with genotype 3, 4% with mixed genotype, and less than 1% each with genotypes 4, 5, and 6(67).
In last few years, the natural history of chronic HCV infection has been better understood. In last few years considerable progress has been made in the knowledge of epidemiology, natural history, factors influencing the course of liver diases and mainly the efficacy of therapy. Still important efforts are needed for screening campaigns for the early diagnosis in order to improve the management of these patients.
The principal challenges to reducing this burden lie in the identification and delivery of care to the major infected populations, and the provision of more effective therapies for the eradication of HCV.
Future projections predict a four-fold increase in USA between 1990 and 2015 in persons at risk of chronic liver disease, suggesting a continued increase in the burden of HCV in the US in the foreseeable future(10).
The HCV epidemic is still growing in importance. Although the incidence
of HCV is falling in some countries, the burden of disease
arising from the pool of chronic infection continues to rise. It has been
estimated that, by 2030, HCV will cause substantially higher morbidity
and mortality in industrialized countries than HIV. Urgent intervention
is required to prevent this outcome. Major barriers, however, remain to
the delivery of effective care for HCV, particularly to populations of
IDUs where the prevalence and incidence of HCV is highest.
Investment in more effective treatments for HCV has so far met with
limited success. There are, however, grounds for optimism. National
strategies are beginning to take account to the need to access and treat
HCV in IDUs and new models for the more effective delivery of care
are currently being validated. Further, novel model systems for the
development and screening of HCV drugs will lead to the provision of
new tools with which to reduce the burden of this important disease.
The high mutability of the HCV genome and limited knowledge in the protective immune response following infection has hindered progress in vaccine development. For this reason, no vaccine is available against HCV(6).
Risk factors/ epidemiology of HCV transmission:
Although HCV is most efficiently transmitted by large or repeated percutaneous exposures to blood, other routes, such as sexual transmission, perinatal transmission, and acquisition from mucous membrane exposure, have been described(7).
Hepatitis C virus is most efficiently transmitted by direct percutaneous exposure to infectious blood, such as through blood transfusion from infectious donors and sharing of contaminated equipment among injecting drug users (68). Haemodialysis patients and healthcare workers who are exposed to needlestick injuries in an occupational setting are also at risk from exposure to infectious blood, as are infants born to infected women. In addition, HCV can be transmitted by sexual or household exposure to an infected contact; however, the efficiency of transmission in these settings appears to be low. Although an average prevalence of HCV infection of 4-5% has been found among household and sex contacts of infected persons in a number of studies, most of these studies were conducted in countries where transmission of HCV infection may be associated with common exposures to contaminated equipment used in traditional and non- traditional medical procedures in the past(68, 69).
Hepatitis C is an RNA virus known to infect humans and chimpanzees, causing a similar disease in these 2 species. HCV is the most common cause of transfusionrelated hepatitis, and is one of the leading causes of end-stage-liver disease requiring liver transplantation in the United States. HCV is transmitted most efficiently by parenteral
means, particularly with large or repeated exposure to infected blood products or transplantation of infected tissue or organ grafts, and IVDU. Less frequently, it can be transmitted by mucosal exposures to blood or serum-derived fluids through perinatal or sexual means(17)
Parenteral routes, mainly transfusion of contaminated blood or blood products, use of contaminated syringes, needles, IDUs, transplantation of infected tissue or organ grafts have been considered as the most efficient ways to transmit HCV infection. Though it's less frequent but, HCV can be transmitted by mucosal exposures to blood or serum-derived fluids through perinatal or sexual means (8, 17). Moreover, another major risk factor for acquisition of HCV is intravenous drug abuse(3).
While on one hand regular practice of screening of blood and blood products started in 1991 had lead to a significant decrease in the incidence of transfusion associated HCV in developed countries, due to lack of regular screening in developing countries transfusion related transmission of HCV is still one of the manor cause (reference). Moreover, there is growing evidence about per mucosal spread of HCV among HIV-infected men, who have sex with men (MSM), especially in USA and Europe. The HCV transmission in such cases correlates with the numbers of sexual partners, the sharing of drugs through the nasal or anal route and high-risk sexual practices (70). The risk of HCV transmission from infected mother to infant is estimated < 5%. However, this risk increases more than two folds if the mother is co-infected with HCV and HIV as compared to those infected with HCV alone(12).
The prevalence of HCV infection was higher among non-Hispanic blacks than among non-Hispanic whites and Mexican Americans and higher among men than among women(16, 18). The peak age group of HCV infection, which was 35-39 years in 1988-1994, has increased over time to 45-49 years in 1999-2002. The prevalence of infection was higher in individuals who had ever used injection drugs than in those who had used noninjection drugs or who had never used these drugs. Prevalence also increased with increasing numbers of lifetime sexual partners and was higher among those with a history of blood transfusion before 1992. Taken together,
these findings indicate that most individuals with HCV were born between 1945 and 1964 and can be identified with current screening criteria(16). Associated risk factors included a
history of injection drug use, receipt of blood transfusion prior to 1992, history of tattooing, combat job as a medical worker, history of incarceration over 48 h, more than 15 lifetime sexual partners, and sexual relations with a prostitute(22).
Strategies to prevent and control hepatitis C
Measures to prevent and control hepatitis C are limited. The high mutability of the HCV genome and limited knowledge in the protective immune response following infection has hindered progress in vaccine development. For this reason, no vaccine is available against HCV(9).
The development of a vaccine is not likely in the foreseeable future, and immune globulin is not effective for post-exposure prophylaxis. Currently available prevention measures include primary prevention activities that reduce the risk of becoming infected with HCV and secondary prevention activities that reduce the risk for chronic disease in HCV-infected persons(68).
From a global perspective, the greatest impact on the disease burden associated with HCV infection will likely be achieved by focusing efforts on primary prevention. Primary prevention strategies can reduce or eliminate the risk of transmission from (1) nosocomial exposures, including transfusion of blood and blood products, and other percutaneous exposures to blood such as through use of unsterile medical and dental equipment and unintensional needlesticks and (2) high risk practices (e.g. injecting drug use, unprotected sex with multiple partners).
Measures to prevent HCV transmission from percutaneous exposures to blood in health care and other settings are similar to those for HBV (see above).
The primary methods to prevent HCV transmission from blood and blood products are exclusion of donors who are judged to be at increased risk of infection by history or who have serologic markers of HCV infection. In addition, plasma derivatives (e.g. clotting factor concentrates, immune globulin) should either undergo viral inactivation or be HCV RNA negative by poly-
merase chain reaction. Transmission of HCV associated with high-risk practices (e.g. injecting drug use, unprotected sex with multiple partners) can be prevented by identifying and counseling persons with a history these practices and by educational efforts to prevent initiation of these practices. Primary prevention of drug injection will eliminate the greatest risk factor for HCV infection in many countries. Educational efforts to prevent initiation of drug injection are especially important for children and adolescents because HCV infection is rapidly acquired after initiation of injecting drug use. Although consistent data are lacking about the extent to which sexual activity contributes to HCV transmission, persons having unprotected sex with multiple partners are at risk for sexually-transmitted diseases (e.g. acquired immunodeficiency syndrome, hepatitis B, syphilis, gonorrhea and chlamydia). Community-based services such as drug- and STD-treatment services can also be used to facilitate prevention or reduction of high-risk behaviors. In addition, programs to increase access to sterile syringes (e.g. syringe exchange programs) can be used to promote safer injection practices among injecting drug users(68).
Secondary prevention activities reduce the risk for chronic disease by identifying HCV-infected persons through diagnostic testing and by providing appropriate medical management and antiviral therapy. In particular, counseling of HCV-infected persons to reduce or abstain from alcohol intake may prevent disease progression. Antiviral treatment is also available, and treatment guidelines have been developed. However, treatment is costly and beyond the resources available in many countries. Moreover, the benefits of early detection and treatment of persons with asymptomatic infection have not been clearly established, a high proportion of persons do not respond to currently available treatment, and the long-term benefit of treatment has not been determined(68).
Systematic screening of blood donors is, however, not universal, and new cases of post-transfusion HCV continueto occur in resource poor settings(12). The unintended transmission of HCV during national campaigns, such as that for the parenteral treatment of schistosomiasis in Egypt, has also contributed to a
national prevalence of up to 15% in some countries(44).
Identification of host and viral epide miologic characteristics associated with disease progression may provide important information on the mechanisms through which HCV infection causes hepatic fi brosis/cirrhosis.
The global epidemiology of hepatitis B and C continues to evolve, mostly toward
a decline in the prevalence of the disease. Improvement in the control of hepatitis B
has been largely achieved with implementation of a more global HBV vaccine
program. The most recent available data from 2001 indicate that 126 (66%) of 191
WHO member states had universal infant or childhood HBV vaccination programs.
In the 6 WHO regions, the proportion of children younger than 1 year who were vaccinated
fully was 65% in the Western Pacific region, 58% in the Americas region, 45% in
the European region, 41% in the Eastern Mediterranean region, 9% in the South-East
Asian region, and 6% in the African region. Overall, an estimated 32% of children
younger than 1 year were vaccinated fully with the 3-dose hepatitis B vaccination
series worldwide. Although significant progress has been made, there still is a large
void to be filled in the global prevention of HBV transmission.130
The transmission of HCV has been greatly impacted by mandatory screening of
blood donors in most countries in the world. However, IVDU continues to be a major
source of infection, and the practice may be on the rise in several areas. Continuing
public education regarding the risks of exposure to infected paraphernalia as well
as household items such as razors is necessary. To date, there is no effective vaccine
available for HCV, which greatly limits the ability to prevent the disease from the grass
roots. The efficacy of antiviral therapy for HCV, although steadily escalating, still has
a large room for improvement. Treatment of HCV is also costly and access to the
medications is limited, particularly in underdeveloped countries. Efforts need to be
continued to address these public health issues that afflict many parts of the world.
1. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 1975 Apr 10;292(15):767-70.
2. Alter HJ, Holland PV, Morrow AG, Purcell RH, Feinstone SM, Moritsugu Y. Clinical and serological analysis of transfusion-associated hepatitis. Lancet. 1975 Nov 1;2(7940):838-41.
3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007 May 7;13(17):2436-41.
4. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001 Jul 5;345(1):41-52.
5. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999 Jan;6(1):35-47.
6. WHO. Hepatitis C; 2000 Contract No.: Document Number|.
7. Rosen HR. Primer on hepatitis C for hospital epidemiologists. Infect Control Hosp Epidemiol. 2000 Mar;21(3):229-34.
8. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003 Dec 20;362(9401):2095-100.
9. WHO. Hepatitis C, WHO fact sheet no. 164. 2000.
10. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int. 2009 Jan;29 Suppl 1:1-8.
11. Shah BB, Wong JB. The economics of hepatitis C virus. Clin Liver Dis. 2006 Nov;10(4):717-34.
12. Thomson BJ. Hepatitis C virus: the growing challenge. Br Med Bull. 2009;89:153-67.
13. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1-16.
14. Szabo E, Lotz G, Paska C, Kiss A, Schaff Z. Viral hepatitis: new data on hepatitis C infection. Pathol Oncol Res. 2003;9(4):215-21.
15. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002 Nov;36(5 Suppl 1):S30-4.
16. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006 May 16;144(10):705-14.
17. Te SH JD. Epidemiology of Hepatitis B and C Viruses: A Global Overview. Clin Liver Dis 2010;14:1-21.
18. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999 Aug 19;341(8):556-62.
19. Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health. 2004 Mar;81(1):25-37.
20. Desai RA, Rosenheck RA, Agnello V. Prevalence of Hepatitis C virus infection in a sample of homeless veterans. Soc Psychiatry Psychiatr Epidemiol. 2003 Jul;38(7):396-401.
21. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004 Apr;39(4):1147-71.
22. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007 Jul;42(7):513-21.
23. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000 Oct;90(10):1562-9.
24. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004 Mar;53(3):451-5.
25. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003 Apr;9(4):331-8.
26. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999 Mar 11;340(10):745-50.
27. Gully PR, Tepper ML. Hepatitis C. CMAJ. 1997 May 15;156(10):1427-30.
28. Santos-Lopez G, Sosa-Jurado F, Vallejo-Ruiz V, Melendez-Mena D, Reyes-Leyva J. Prevalence of hepatitis C virus in the Mexican population: a systematic review. J Infect. 2008 Apr;56(4):281-90.
29. Ono-Nita SK, Nita ME, Carrilho FJ. Hepatitis C: facts in numbers. Arq Gastroenterol. 2006 Apr-Jun;43(2):71-2.
30. Sweeting MJ, De Angelis D, Brant LJ, Harris HE, Mann AG, Ramsay ME. The burden of hepatitis C in England. J Viral Hepat. 2007 Aug;14(8):570-6.
31. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007 Feb;14(2):107-15.
32. Balogun MA, Ramsay ME, Hesketh LM, Andrews N, Osborne KP, Gay NJ, et al. The prevalence of hepatitis C in England and Wales. J Infect. 2002 Nov;45(4):219-26.
33. Balogun MA, Murphy N, Nunn S, Grant A, Andrews NJ, Teo CG, et al. Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics. Epidemiol Infect. 2009 Jul;137(7):980-7.
34. Kelly H, Riddell MA, Gidding HF, Nolan T, Gilbert GL. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine. 2002 Aug 19;20(25-26):3130-6.
35. Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis. 2006;6:93.
36. Hughes G, Simms I, Leong G. Data from UK genitourinary medicine clinics, 2006: a mixed picture. Sex Transm Infect. 2007 Oct;83(6):433-5.
37. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis. 2002 May;2(5):293-302.
38. Jeannel D, Fretz C, Traore Y, Kohdjo N, Bigot A, Pe Gamy E, et al. Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. J Med Virol. 1998 Jun;55(2):92-7.
39. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ. 1999;77(10):789-800.
40. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ. 1999;77(10):801-7.
41. Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet. 2000 Sep 9;356(9233):904-7.
42. Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail NN, et al. Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg. 2002 Oct;67(4):436-42.
43. Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology. 2006 May;43(5):915-22.
44. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000 Mar 11;355(9207):887-91.
45. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer. 2007 Apr 10;96(7):1127-34.
46. Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. Int J Infect Dis. 2006 Jul;10(4):272-7.
47. Raja NS, Janjua KA. Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect. 2008 Feb;41(1):4-8.
48. Mukhopadhya A. HCV: the Indian scenario. Trop Gastroenterol. 2006 Jul-Sep;27(3):105-10.
49. Jha J, Banerjee K, Arankalle VA. A high prevalence of antibodies to hepatitis C virus among commercial plasma donors from Western India. J Viral Hepat. 1995;2(5):257-60.
50. Chowdhury A, Santra A, Chaudhuri S, Dhali GK, Maity SG, Naik TN, et al. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology. 2003 Apr;37(4):802-9.
51. Wiwanitkit V. Anti HCV seroprevalence among the voluntary blood donors in Thailand. Hematology. 2005 Oct;10(5):431-3.
52. Luksamijarulkul P, Thammata N, Sujirarat D, Tiloklurs M. Hepatitis C virus infection among Thai blood donors: antibody prevalence, risk factors and development of risk screening form. Southeast Asian J Trop Med Public Health. 2004 Mar;35(1):147-54.
53. Jittiwutikarn J, Thongsawat S, Suriyanon V, Maneekarn N, Celentano D, Razak MH, et al. Hepatitis C infection among drug users in northern Thailand. Am J Trop Med Hyg. 2006 Jun;74(6):1111-6.
54. Hansurabhanon T, Jiraphongsa C, Tunsakun P, Sukbunsung R, Bunyamanee B, Kuirat P, et al. Infection with hepatitis C virus among intravenous-drug users: prevalence, genotypes and risk-factor-associated behaviour patterns in Thailand. Ann Trop Med Parasitol. 2002 Sep;96(6):615-25.
55. Luksamijarulkul P, Deangbubpha A. Hepatitis C antibody prevalence and risk factors of some female sex workers in Thailand. Southeast Asian J Trop Med Public Health. 1997 Sep;28(3):507-12.
56. Sulaiman HA, Julitasari, Sie A, Rustam M, Melani W, Corwin A, et al. Prevalence of hepatitis B and C viruses in healthy Indonesian blood donors. Trans R Soc Trop Med Hyg. 1995 Mar-Apr;89(2):167-70.
57. Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol. 2004 Feb;33(1):182-8.
58. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008 Oct;122(10):990-1003.
59. Higuchi M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis. 2002 Jun;55(3):69-77.
60. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology. 2002;62 Suppl 1:8-17.
61. Iino S. Relationship between infection with hepatitis C virus and hepatocellular carcinoma in Japan. Antivir Ther. 1998;3(Suppl 3):143-6.
62. Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol. 2003 Oct;32(5):717-24.
63. Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol. 2003 Feb;26(2):171-84.
64. Armstrong GL, Williams IT, Maga UA, Viali S, Kuhnert WL, McGarvey ST. Hepatitis C virus infection in Samoa and American Samoa. Am J Trop Med Hyg. 2006 Feb;74(2):261-2.
65. Muhlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9:34.
66. Nguyen MH, Keeffe EB. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis. 2005 Aug;9(3):411-26, vi.
67. Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat. 2000 May;7(3):196-202.
68. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine. 1999 Mar 26;17(13-14):1730-3.
69. Ndimbie OK, Kingsley LA, Nedjar S, Rinaldo CR. Hepatitis C virus infection in a male homosexual cohort: risk factor analysis. Genitourin Med. 1996 Jun;72(3):213-6.
70. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007 May 11;21(8):983-91.
Recommendations for prevention and control of hepatitis C virus (HCV) infection
and HCV related chronic disease. MMWR Recomm Rep 1998;47(RR-19):1-39